Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.

Tralokinumab, a fully human IgG4 monoclonal antibody, specifically neutralizes IL-13. The ATMOSPHERE clinical development program comprised four randomized, placebo-controlled clinical trials and an open-label study that aimed to assess the efficacy and safety of tralokinumab for the treatment of severe, uncontrolled asthma. The two pivotal trials (STRATOS 1 and STRATOS 2; NCT02161757 and NCT02194699) evaluated the efficacy and safety of tralokinumab, with STRATOS 1 identifying a subgroup most likely to demonstrate enhanced response to treatment. Further trials have assessed the ability of tralokinumab to reduce oral corticosteroid use (TROPOS; NCT02281357) and determined its mechanistic effects (MESOS; NCT02449473). An open-label study in Japanese individuals (NCT02902809) assessed the long-term safety and tolerability of tralokinumab in this population.

• Publication year

  2018

• Venue

  Immunotherapy

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2017-0191PMID 29536781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

  2018cited by this paper
• Development and analytical performance of a new ARCHITECT automated dipeptidyl peptidase-4 immunoassay

  2017cited by this paper
• New Anti‐Eosinophil Drugs for Asthma and COPD: Targeting the Trait!

  2017cited by this paper
• Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.

  2017cited by this paper
• The current and future role of biomarkers in type 2 cytokine‐mediated asthma management

  2017cited by this paper
• Development of a new ARCHITECT automated periostin immunoassay.

  2017cited by this paper
• A European Respiratory Society technical standard: exhaled biomarkers in lung disease

  2017cited by this paper
• Periostin upregulates the effector functions of eosinophils.

  2016cited by this paper
• Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs

  2016cited by this paper
• Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

  2016cited by this paper
• A Mathematical Modeling Approach to Understanding the Effect of Anti‐Interleukin Therapy on Eosinophils

  2016cited by this paper
• Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

  2016cited by this paper
• Clinical profile of patients with adult-onset eosinophilic asthma

  2016cited by this paper
• Evidence for Human Adaptation and Foodborne Transmission of Livestock-Associated Methicillin-Resistant Staphylococcus aureus

  2016cited by this paper
• Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

  2016cited by this paper
• Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

  2016cited by this paper
• Emergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond.

  2016cited by this paper
• Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells

  2016cited by this paper
• Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

  2016cited by this paper
• Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.

  2015cited by this paper
• Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

  2015cited by this paper
• Biomarkers and severe asthma: a critical appraisal

  2015cited by this paper
• TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma

  2015cited by this paper
• Strategies targeting the IL-4/IL-13 axes in disease.

  2015cited by this paper
• STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma

  2015cited by this paper
• Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

  2015cited by this paper
• MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma

  2015cited by this paper
• Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

  2015cited by this paper
• The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review

  2015cited by this paper
• Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives

  2015cited by this paper
• Characterisation of an OCS-dependent severe asthma population treated with mepolizumab

  2014cited by this paper
• Mepolizumab treatment in patients with severe eosinophilic asthma.

  2014cited by this paper
• Persistent elevation of exhaled nitric oxide and modification of corticosteroid therapy in asthma.

  2013cited by this paper
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

  2013cited by this paper
• Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-&bgr;1 in airway fibroblasts in asthma

  2013cited by this paper
• α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin.

  2013cited by this paper
• Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

  2012cited by this paper
• A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

  2012cited by this paper
• Asthma outcomes: biomarkers.

  2012cited by this paper
• Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

  2012cited by this paper
• An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications

  2012cited by this paper
• Asthma phenotypes: the evolution from clinical to molecular approaches

  2012cited by this paper
• An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

  2011cited by this paper
• Lebrikizumab treatment in adults with asthma.

  2011cited by this paper
• Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein.

  2009cited by this paper
• T-helper type 2-driven inflammation defines major subphenotypes of asthma.

  2009cited by this paper
• The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

  2009cited by this paper
• IL‐13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells

  2008cited by this paper
• Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses

  2008cited by this paper
• Early identification of atopy in the prediction of persistent asthma in children.

  2008cited by this paper
• Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma.

  2007cited by this paper
• IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.

  2006cited by this paper
• Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture.

  2006cited by this paper
• IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis

  2006cited by this paper
• Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

  2006cited by this paper
• IgE antibody quantification and the probability of wheeze in preschool children.

  2005cited by this paper
• The global burden of asthma: executive summary of the GINA Dissemination Committee Report

  2004cited by this paper
• Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)‐β1, TGF‐β2, interleukin (IL)‐4 and IL‐13 after segmental allergen challenge and their effects on α‐smooth muscle actin and collagen III synthesis by primary human lung fibroblasts

  2004cited by this paper
• A Critical Role for Eosinophils in Allergic Airways Remodeling

  2004cited by this paper
• NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response

  2001cited by this paper
• Immuno‐regulatory cytokines in asthma: IL‐15 and IL‐13 in induced sputum

  2001cited by this paper
• Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma

  1999cited by this paper
• Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma.

  1997cited by this paper
• Interleukin-13 and interleukin-4 are coexpressed in atopic asthma.

  1996cited by this paper
• Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells.

  1993cited by this paper

• Type 2 Inflammation and Its Role in Dermatologic Diseases

  2025cites this paper
• Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications

  2025influential citation
• Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.

  2025cites this paper
• Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy.

  2024cites this paper
• Genetically engineered biological drugs in therapeutic practice

  2024cites this paper
• IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis

  2023cites this paper
• Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

  2022cites this paper
• Targeted therapy in eosinophilic chronic obstructive pulmonary disease

  2021cites this paper
• Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total

  2021cites this paper
• Anti-Interleukin Biologics for the treatment of the Atopic March Diseases

  2021cites this paper
• Recent Advances in the Inhibition of the IL-4 Cytokine Pathway for the Treatment of Allergen-Induced Asthma

  2021cites this paper
• New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding

  2020cites this paper
• Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

  2019cites this paper
• Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

  2019cites this paper
• Biologic agents for asthma treatment

  2019cites this paper
• Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma

  2019cites this paper
• Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.

  2018cites this paper
• Monoclonal antibodies for the treatment of atopic dermatitis

  2018cites this paper
• Tralokinumab for severe , uncontrolled asthma : the STRATOS 1 and 2 randomised , placebo-controlled , phase 3 clinical trials

  2018cites this paper
• Immunotherapy Foreword 2018.

  2018cites this paper
• Targets of monoclonal antibodies for immunological diseases

  2018cites this paper